MRPS17P9

Across TCGA pan-cancer cohorts, MRPS17P9 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated MRPS17P9 data layer.

The strongest signal is observed in thymoma (THYM), where higher MRPS17P9 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MRPS17P9 expression acts as an unfavorable survival marker, although some lineages such as LIHC and BRCA show a favorable association.

THYM, DLBC, and LIHC are the cancer types where MRPS17P9 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Tertile	II,III,IV	0.781	0.964	.002	63	view →
DLBC	DFS	Tertile	IV	0.120	0.683	.001	45	view →
LIHC	OS	Tertile	III,IV	0.925	0.285	.009	42	view →
HNSC	DFS	Tertile	IV	0.237	0.555	.007	36	view →
ACC	DFS	Tertile	All	0.193	0.659	.004	36	view →
READ	OS	Tertile	II,III,IV	0.763	0.947	.007	30	view →
CESC	OS	Tertile	IV	0.095	0.592	.004	18	view →
LGG	OS	Tertile	All	0.839	0.912	.010	18	view →
BRCA	DFS	Tertile	II,III,IV	0.958	0.883	.046	9	view →
SARC	OS	Tertile	All	0.955	0.826	.028	9	view →
GBM	OS	Quartile	All	0.482	0.273	.029	7	view →
LUSC	DFS	Tertile	All	0.923	0.672	.047	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

MRPS17P9–THYM (OS)

Open the THYM breakdown →